Morgan Stanley Discount Zert BNTX.../ DE000ME5LM40 /
2024-06-21 2:01:46 PM | Chg.-0.08 | Bid2:11:07 PM | Ask2:11:07 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
54.09EUR | -0.15% | 54.10 Bid Size: 200 |
54.87 Ask Size: 200 |
BioNTech SE | - USD | 2024-12-31 | Call |
GlobeNewswire
06-01
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
05-29
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
05-28
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire
05-21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
05-21
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
05-17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
05-17
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
05-09
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
05-02
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
04-22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
04-10
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first...
GlobeNewswire
04-07
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
03-28
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
03-20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
03-20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
03-14
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates